Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of July 20th – 26th, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view full article.

10. Red White & Bloom to Acquire Premium Cannabis Brand with Over $70 Million in Annualized Revenue

Platinum Vape Boasts an Annualized Revenue Run Rate of Over USD $70 Million and EBITDA of Between $17.5 Million to $21 Million

Red White & Bloom (OTCQX: RWBYF) announced the signing of a binding LOI to acquire a group of California-based companies operating under the name Platinum Vape. Platinum Vape currently has its premium products, including vapes, flower, edibles and pre-rolls in over 700 retail locations across Michigan, California and Oklahoma.

READ FULL RWB PLATINUM VAPE ARTICLE

9. Champignon Brands Files Business Acquisition Reports and Appoints New Director

Champignon Also Announced the Appointment of Company CEO, Dr. Roger McIntyre, to its Board of Directors

Champignon Brands (OTCQB: SHRMF) announced on Friday it filed the required Business Acquisition Reports (BAR) in relation to the company’s previously announced acquisitions of Artisan Growers, Novo Formulations and Tassili Life Sciences. Dr. McIntyre will replace Pat McCutcheon as a director on the company’s board. Mr. McCutcheon, CEO of MediPharm Labs (OTCQX: MEDIF), will remain with the company in an advisory capacity, which will permit him increased mobility to assist Champignon with ongoing and planned capital markets initiatives.

READ FULL CHAMPIGNON ARTICLE

8. FDA and Psychedelics: What it Has, What it Wants

Any New Drug Therapy That Can Be Manufactured and Sold in the U.S. Has to Have the Approval of the FDA. That’s the Deal

Recently, the FDA has had to face a perplexing issue with plant-based Psychedelic substances that have found new meaning within the health and wellness community—Cannabis, Psilocybin, MDMA, Ketamine and LSD.

READ FULL FDA ARTICLE

7. Aleafia Health Approved By Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO

SPRAVATO (Esketamine) Nasal Spray is Approved By the U.S. FDA and Health Canada

Aleafia Health (OTCQX: ALEAF) announced that Johnson & Johnson (NYSE: JNJ) owned company Janssen Pharmaceuticals has approved its wholly-owned subsidiary, Canabo Medical as an administrator and prescriber of antidepressant SPRAVATO (Esketamine) nasal spray.

READ FULL ALEAFIA HEALTH ARTICLE

6. NEO CEO: Psychedelics an “Incredible Opportunity” to Do Good

Jos Schmitt of the NEO Exchange is All in on the Medical Benefits of Psychedelic Drugs

The NEO has been heavily involved in the advancement of Psychedelic Stocks as the exchange includes one of the biggest names in the nascent industry: MindMed (OTCQB: MMEDF). The Psychedelics drug development firm went public back in March with the backing of noteworthy investors Kevin O’Leary and Canopy Growth (NYSE: CGC) founder and former CEO Bruce Linton.

READ FULL PSYCHEDELICS OPPORTUNITY ARTICLE

5. Numinus Wellness Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to .05 Million

Each Unit Will Consist of One Common Share of the Company and One-Half of One Common Share Purchase Warrant

Numinus Wellness (OTC: LKYSD) announced it has entered into an engagement letter with Mackie Research to conduct a best-efforts offering of up to 15 million units at a price of $0.27 for gross proceeds of up to $4.05 million. Numinus intends to use the proceeds of the offering for MDMA and Psilocybin Compassionate Access protocol implementation to make these drugs accessible to specific patient groups before they are available on the market.

READ FULL NUMINUS ARTICLE

4. U.S. Cannabis Stocks: A Good Investment In A Bad Economy

A Host of Factors Are Brewing That Could Cause a Powerful Tailwind for the U.S. Cannabis Industry

Many U.S. multi-state operators (MSOs), particularly those with a strong focus on operating fundamentals, have already started to see their valuations rebound off the lows from late 2019 and early 2020. These U.S. Pot Stocks should still have lots of room to grow. In fact, a strong argument can be made that many American Cannabis Stocks are attractively valued compared to their current and anticipated long-term growth rates.

READ FULL U.S. POT STOCKS ARTICLE

3. Champignon Brands Files BAR Reports Signal Beginning of End to Stock Halt

Champignon Brands Investors Can Finally Breathe a Sigh of (Partial) Relief

On Wednesday, Champignon Brands (OTCQB: SHRMF) filed three separate Business Acquisition Reports (BAR) which, upon the satisfaction of regulators, signals the halt in their Canadian Securities Exchange listing—in effect since June 22— may soon be lifted.

READ FULL CHAMPIGNON BRANDS ARTICLE

2. Curaleaf and Grassroots Finally Merge, Creating Largest Marijuana Company in the World

The Deal Was Originally Announced Just Over One Year Ago

More than a year after it was first agreed upon, a big tie-up in the marijuana industry has finally been completed. Curaleaf (OTCQX: CURLF) announced Thursday it is now the owner of Grassroots, which it says makes it the largest cannabis business in the world in terms of revenue.

READ FULL CURALEAF ARTICLE

1. American Cannabis Stocks Are Looking Cheap, Stifel Says

Investors Burned By the Year-Long Slump in Cannabis Will Be Happy to Hear That Things Are Looking up for Cannabis Stocks —in the U.S., at Least

That’s according to Stifel GMP analyst Andrew Partheniou who delivered a “Re-initiating on Cannabis” report to clients on Wednesday with a number of “Buy” ratings on Cannabis Stocks including Curaleaf (OTCQX: CURLF), Trulieve (OTCQX: TCNNF), Green Thumb Industries Inc (OTCQX: GTBIF) and Cresco Labs (OTCQX: CRLBF).

READ FULL U.S. CANNABIS STOCKS ARTICLE

Photo by Esteban Lopez on Unsplash

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Source News